Morrow George J
MORROW GEORGE J, DIR, reported a transaction classified as exercise at NEUROCRINE BIOSCIENCES INC involving 300.000000 shares for an estimated $0.00. Reported holdings after the transaction were 14700.000000 shares. The stored filing text includes a detected 10b5-1 reference.
- Trade date
- Oct 30, 2026
- Filing date
- Nov 03, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
NBIX price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0001068754-26-000009 Non-Qualified Stock Option
- Transaction date
- Oct 30, 2026 Filed Nov 03, 2026, 11:52 PM · 4d delay
- Shares
- 300 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 14,700 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-20 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases. - tenb5_1_detected-10 points
is_10b5_1 = true
Stored filing content includes detected 10b5-1 language.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
No officer title
- F1
The dispositions reported in this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026. Additionally,
Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- F2
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $144.32 to $145.28. The Reporting Person has provided to the issuer, and
- (9 footnotes)
will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $145.35 to $146.34. The Reporting Person has provided to the issuer, and
- F4
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $146.38 to $147.26. The Reporting Person has provided to the issuer, and
- F5
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $163.21 to $164.01. The Reporting Person has provided to the issuer, and
- F6
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $164.22 to $165.20. The Reporting Person has provided to the issuer, and
- F7
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $165.26 to $166.24. The Reporting Person has provided to the issuer, and
- F8
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $166.26 to $167.20. The Reporting Person has provided to the issuer, and
- F9
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.27 to $168.18. The Reporting Person has provided to the issuer, and
- F10
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.27 to $169.10. The Reporting Person has provided to the issuer, and
- F11
The option was granted May 22, 2017 and vested in 12 equal monthly installments beginning June 22, 2017. These options were scheduled to expire on May 22, 2027.
0 other transactions
0 recent txs